Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of 18 F-THK5351 PET to predict the prognosis for mild cognitive impairment (MCI) due to Alzheimer's disease

Trial Profile

Study of 18 F-THK5351 PET to predict the prognosis for mild cognitive impairment (MCI) due to Alzheimer's disease

Completed
Phase of Trial: Phase II

Latest Information Update: 28 May 2018

At a glance

  • Drugs Fluorine 18 THK 5351 (Primary)
  • Indications Alzheimer's disease; Mild cognitive impairment
  • Focus Diagnostic use
  • Most Recent Events

    • 28 May 2018 New trial record
    • 05 May 2018 Results presented at the 2018 Annual Scientific Meeting of the American Geriatrics Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top